- 1 Title: Vaccination status and re-infection among COVID patients admitted in COVID High
- 2 Dependency Unit (HDU) of a tertiary hospital in Eastern Nepal: A cross-sectional study
- 3 Short title: Vaccination status and re-infection among COVID patients
- 4 Sujan Kafle¹, Varsha Chhetri¹, Joshan Lal Bajracharya², Lenish Pokharel¹, Suyash Dawadi¹, Ujwal Basnet¹,
- 5 Shreya Dhungana¹, Durga Neupane¹
- 7 1. B.P. Koirala Institute of Health Sciences, Dharan, Nepal
- 8 2. Consultant Anesthesiologist, Department of Anesthesiology and Critical Care, Provincial 9 Hospital Bhadrapur, Jhapa
- 10 Authors:

- Sujan Kafle (Corresponding author) 11
- 12 Email: sujank79@gmail.com
- 13 Varsha Chhetri
- 14 Email: chhetrivarsha16@gmail.com
- 15 Dr. Joshan Lal Bajracharya
- 16 Email: bajracharyajoshanlal@gmail.com
- 17 Lenish Pokharel
- 18 Email: lenishpokharel@gmail.com
- 19 Suyash Dawadi
- 20 Email: suyash.dawadi@gmail.com
- 21 Ujwal Basnet
- 22 Email: ujwalbpkihs@gmail.com
- 23 Shreya Dhungana
- 24 Email: shreyadhungana@gmail.com
- 25 Durga Neupane

27

28 29

30

26 Email: neupanedurga26@gmail.com

Abstract

31

3233

34

3536

37

38

39 40

45

46

57

58

65

66

67

68

Introduction:

The relationship between COVID-19 vaccination and Coronavirus disease severity and outcomes remain topics of significant interest. This cross-sectional study done among COVID-19 patients admitted to the High-dependency unit of a tertiary hospital in Eastern Nepal aimed to assess the association between vaccination status, prior infection, and disease outcomes, and the modification of these associations by the presence or absence of comorbidities.

Methodology:

- Demographic and clinical data were collected from 102 COVID-19 patients admitted to the High-
- 42 Dependency Unit of Mechi Zonal Hospital, including information on vaccination status,
- comorbidities, disease severity, and outcomes. Statistical analysis, including chi-square tests and
- Fisher's exact tests, was performed to examine the associations.

Results:

- 47 Among the study participants, 49% had received at least one dose of COVID-19 vaccine.
- 48 Vaccinated individuals had a significantly lower rate of severe disease compared to non-vaccinated
- individuals ($\chi^2=10.05$, p=0.002). Recovery and mortality rates did not differ significantly between
- the two groups ($\chi^2=1.008$, p=0.315). However, when stratified by comorbidities, vaccinated
- 51 individuals with comorbidities had higher recovery rates compared to non-vaccinated individuals
- 52 (85.29% vaccinated vs. 25.00% non-vaccinated, Fisher's exact test p=0.024). Vaccinated
- 53 individuals, both with and without comorbidities, had lower rates of severe disease compared to
- 54 non-vaccinated individuals. However, the association was found to be significant only in
- 55 individuals with comorbidities (12.50% vaccinated without comorbidities vs. 47.92% non-
- vaccinated, p=0.017; 23.53% vaccinated with comorbidities vs. 75.00% non-vaccinated, p=0.065).

Conclusion:

- 59 Our findings suggest that COVID-19 vaccination is associated with a reduced risk of severe
- disease among individuals with or without comorbidities and decreased risk of mortality among
- 61 those with comorbidities. However, larger studies are needed to validate these findings and further
- explore the impact of vaccination on disease outcomes. These findings support the ongoing efforts
- 63 to promote COVID-19 vaccination as a crucial public health intervention.
- 64 Keywords: COVID-19, vaccination status, comorbidities, disease severity, outcomes.

Introduction

The novel coronavirus disease, COVID-19, has imposed significant challenge for public health officials and healthcare providers. According to the World Health Organization, over 6.9 million deaths have been implicated to COVID-19.¹ Many questions are yet to be explored and answered regarding the virus, SARS-CoV-2. Much is understood about the viral infection and the modes of transmission, but the timing, magnitude, and longevity of humoral immunity after natural infection and vaccination are still a subject of study. ^{2–4}

A breakthrough infection is an infection with a virus, bacterium or other germ after you have been vaccinated.⁵ Vaccine breakthrough infections are expected. COVID-19 vaccines are effective at preventing most infections. However, like other vaccines, they are not 100% effective.⁶ Fully vaccinated people with a vaccine breakthrough infection are less likely to develop serious illness than those who are unvaccinated and get COVID-19.⁶

For epidemiologic purposes, severe Covid-19 in adults is defined as dyspnea, a respiratory rate of 30 or more breaths per minute, a blood oxygen saturation of 93% or less, a ratio of the partial pressure of arterial oxygen to the fraction of inspired oxygen (PaO2:FIO2) of less than 300 mm Hg, or infiltrates in more than 50% of the lung field.^{7,8}

- The recommended dosage of AstraZeneca (ChAdOx1-S [recombinant] vaccine) is two doses given intramuscularly (0.5ml each) with an interval of 8 to 12 weeks. 9,10 WHO recommends two doses of Janssen Ad26.COV2.S COVID-19 vaccine. The second dose should be given 2-6 months after the first dose. 11 The recommended dose of Sinopharm COVID-19 vaccine (Verocell) is 2 doses (0.5 mL each) at a recommended interval of 3 to 4 weeks. 12
- We conducted this study to try and attempt to answer few questions first, among the hospitalized participants, whether there was a significant difference in disease severity and mortality among the vaccinated and non-vaccinated participants; second, whether there was a significant difference between disease severity and mortality among reinfected individuals and new cases.

In summary, the aim of this study is to evaluate the effectiveness of vaccination in preventing severe disease and mortality in individuals with and without comorbidities. We aim to assess the impact of vaccination on the adverse outcomes, including severe disease and mortality by analyzing the vaccination status of participants who experienced such outcomes. We believe that the findings of this study will contribute to our understanding of the role of vaccination in mitigating the severity of illness and reducing mortality, particularly in individuals with underlying comorbidities. This knowledge can inform public health strategies and guide decision-making regarding vaccination recommendations for vulnerable populations.

Material and Methods

109

110

115

123

129 130

131

132

- 111 The required information and data for this study were collected from various sources like PubMed, 112 World Health Organization (WHO), Johns Hopkins Medicine, Center for Disease Control (CDC) 113 and the New England Journal of Medicine (NEJM). The key terms used were COVID-19. 114 coronavirus, SARS-CoV-2, breakthrough infection, vaccination, and severe COVID-19.
- 116 A descriptive cross-sectional study was carried out among the cases of COVID-19 admitted in the High Dependency Unit (HDU) of Mechi Zonal Hospital, Nepal for two months (January 26th to 117 118 March 26th, 2022). The phone number of the participants or their guardians were obtained from 119 the registry of the HDU. The participants or their guardians (in case of the death of the participant) were contacted via telephone and the information sheet was read out to them in the Nepali language 120 121 (which they preferred). The participants (or their guardians, in case of the participant's death) who provided verbal consent for the study were enrolled in the study. 122
- 124 The ethical clearance was obtained from the Nepal Health Research Council on April 17th, 2022. 125 The study was started on June 1st, 2022, and the data collection was completed on June 18th, 2022. 126 We used a pre-tested questionnaire for conducting this study. With the help of the questionnaire,

127 data were collected from the participants or their guardians. The information about the hospital 128

stay of the participants was obtained from the medical records section of the hospital.

The data was collected, tabulated, and statistically analyzed using Statistical Package for Social Sciences version 25.

Results 133 During the study period, there were a total of 120 cases of COVID-19 admitted in the High 134 Dependency Unit of Mechi Zonal Hospital, Nepal. 18 participants or their guardians either 135 136 declined to participate or couldn't be contacted. So, we collected the data from 102 participants or 137 their guardians for the study. 138 139 Among the study participants, 52% were male and 48% were female. The mean age of our study 140 population was 48.34 ± 26.15 years with a minimum age of 11 days and a maximum age of 96 141 years. The age category with the highest representation was 18-59 years, comprising 43.14% of 142 the participants (Figure 1). 143 144 Among the study participants, 4.9% (n=5) had a history of prior documented infection with 145 COVID-19 (Figure 2). 146 147 The majority of the participants of the age group 18-59 years (56.82%) and those aged 60 years 148 and greater (60.98%) were vaccinated. No participants below 18 years of age were vaccinated 149 (Figure 3). 150 151 152 Among the study participants, 49% (n=50) had received at least one dose of a COVID-19 vaccine 153 while 51% (n=52) had not. Among the vaccinated participants, the majority of them (46%) had 154 received AstraZeneca (ChAdOx1-S [recombinant]) vaccine followed by Sinopharm COVID-19 155 vaccine (Verocell) (34%) and Janssen Ad26.COV2.S COVID-19 vaccine (20%) (Figure 4). 156 157 158 Among the vaccinated participants, 50% (n=25) had received their last dose of vaccination within 159 3 months of admission and an equal percentage of participants had received their last dose greater 160 than 3 months prior to admission (Figure 5). 161 162 Among the vaccinated participants, 46% (n=23) had received only a single dose, while 54% (n=27) had received 2 doses of the vaccines (Figure 6). All of the participants who had received Janssen 163 164 Ad26.COV2.S COVID-19 vaccine had received only one dose whereas 69.57% (n=16) of the participants receiving the AstraZeneca (ChAdOx1-S [recombinant]) vaccine (n=23) and 165 64.71% (n=11) of the participants receiving Sinopharm COVID-19 vaccine (Verocell) had 166 167 received two doses of the vaccine (Figure 7). 168

170 171 172 173 When the participants received two doses of the vaccine, the majority of them had not followed 174 the dosing interval recommended by WHO. Only 11.76% (n=2) of participants receiving the Sinopharm COVID-19 vaccine (Verocell) and 17.39% (n=4) receiving the AstraZeneca 175 176 (ChAdOx1-S [recombinant] vaccine) had adhered to the dosing interval recommended by the 177 World Health Organization (WHO) (Table 1). Overall, only 22.22% of participants (n=6) had 178 received the vaccines as per the WHO recommended interval, while 77.78% of participants 179 (n=21) had not (Figure 8). 180 181 **Association Analysis** 182 Vaccinated participants (n=50) had a significantly lower rate of severe disease compared to non-183 vaccinated participants (n=52) (20.00% vaccinated vs. 50.00% non-vaccinated, $\chi^2=10.05$, 184 p=0.002) (Figure 9). 185 We examined the outcomes of participants in terms of recovery and mortality rates in our study. 186 Among the vaccinated participants (n=50), 44 (88.00%) recovered, while 6 (12.00%) expired. 187 Similarly, among the unvaccinated individuals (n=52), 42 (80.77%) recovered, and 10 (19.23%) 188 expired (Table 2, Figure 10). No statistically significant difference was observed in recovery and 189 mortality rates between the vaccinated and unvaccinated groups ($\gamma^2=1.008$, p=0.315). 190 191 192 We analyzed the association between severity and vaccination status as well as between outcome 193 and vaccination status among patients who received different types of vaccines (Table 3). There 194 was no significant difference between severe and non-severe disease in the participants who 195 received different types of vaccines (Fisher's exact test, p = 0.296). Also, there was no significant 196 association between different vaccine types and outcome (Fisher's exact test, p = 0.740) 197 198 Among the vaccinated participants receiving two doses of the vaccine, we analyzed the association 199 between adherence to recommended dosing intervals and severity of infection or mortality (Table 200 4). There were no statistically significant associations between participants who adhered to the 201 recommended dosing interval and who did not in terms of severity (p = 0.56) or mortality (p = 0.56) 202 1.00). 203 204 Participants who received their last dose of vaccination within 3 months of admission (n=25) had 205 a significantly lower rate of severe disease compared to those who received their last vaccine

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

dose more than 3 months prior (8% vaccinated within 3 months vs. 24% vaccinated more than 3 months, $\chi^2=4.500$, p=0.034). Additionally, all participants who received their last vaccine dose within 3 months recovered, while 24% of those who received their last dose more than 3 months ago expired (Table 5). The association was found to be statistically significant (p=0.022, Fisher's exact test). We stratified the severity and outcome in vaccinated and non-vaccinated participants in terms of whether or not they had any comorbidities (Table 6). The major co-morbidities noted in our study participants were hypertension, diabetes mellitus, and chronic obstructive pulmonary disease. Vaccinated participants with or without comorbidities had significantly lower rates of severe disease compared to non-vaccinated participants (Fisher's exact test, p = 0.065 for participants without comorbidities; χ^2 =6.323, p = 0.017 for participants with comorbidities). Vaccinated participants with comorbidities had significantly lower mortality rate (14.71%) compared to non-vaccinated participants (75.00%), indicating an approximately 5-fold higher mortality rate among the non-vaccinated group (Fisher's exact test, p=0.024). With comorbidities absent, we found no statistical significance through Fisher's exact test (p=0.667) between the mortality rates of vaccinated and unvaccinated groups. Also, we stratified the severity of infections and outcomes according to age factor (Table 7). Statistical analysis showed no significant difference between severity and vaccination status among participants aged 60 years and above (Fisher's exact test, p = 0.287). But there was a significant association between severity and vaccination status among the participants of the age group 18-59 years (χ^2 =8.481, p = 0.004). There was no significant difference in outcome and vaccination status among the participants of the age group 18-59 years (Fisher's exact test, p = 0.210) and age group \geq =60 years (Fisher's exact test, p = 1.00) We analyzed the association between prior infection and severity as well as outcome of current infection (Table 8). Fisher's exact test failed to reveal a significant association between prior infection and current infection severity (p = 0.158) or outcome (p = 1.0).

Discussion

- 241 The purpose of this study was to look into the relationship between vaccination status, re-infection,
- 242 and clinical outcomes among patients admitted to the COVID High Dependency Unit (HDU). We
- 243 looked into things like the type of COVID-19 vaccine used, the number of vaccine doses given,
- 244 adherence to recommended dosing intervals, time since vaccination, and the effect of vaccination
- 245 on severity and outcome. Furthermore, we investigated the impact of comorbidities and prior
- 246 infection on disease severity and outcome. We believe that this study will contribute to the
- 247 understanding of COVID-19 vaccine effectiveness by guiding clinical decision-making and public
- 248 health interventions. We compare our findings to the existing literature, identify limitations, and
- 249 suggest future research directions.
- 250 The gender distribution among participants in our study was relatively balanced, with 52% male
- 251 and 48% female. This gender distribution reflects our study population's inclusion of both males
- 252 and females, allowing for a more representative analysis. In terms of vaccination status, we found
- 253 that 49% of participants had received at least one dose of COVID-19 vaccine, while 51% had not
- 254 received any. This distribution sheds light on vaccination coverage in the study population,
- 255 indicating that a sizable proportion of people had not yet received any COVID-19 vaccine at that
- 256 time. This finding may have implications for how the results of the study on the relationship
- 257 between vaccination status and the severity or outcome of the current infection are interpreted.
- 258 Our finding showed that vaccination with the COVID-19 vaccine is associated with a significantly
- 259 lower risk of severe disease is consistent with the studies in the past which investigated the
- association between vaccination and disease severity. 13-15 However, unlike these studies, our study 260
- failed to demonstrate a significant relationship between vaccination status and the outcome 261
- 262 (recovery or death).
- 263 One study by Bernal et al. showed that one dose of either BNT162b2 or ChAdOx1-S offered
- 264 protection against severe disease for > 6 weeks. Our study finding is in line with this finding as it
- 265 showed that the vaccinated patients who were infected with COVID-19 within 3 months of
- vaccination had a significantly lower risk of severe disease and mortality. ¹⁶ 266
- 267 Our study had some limitations. First, a relatively small sample size in our study may limit the
- generalizability of the findings to broader populations. Second, the study design was cross-268
- 269 sectional, which limits our ability to establish causal relationships. Longitudinal studies or
- 270 randomized controlled trials would provide stronger evidence of the impact of vaccination and
- 271 comorbidities on disease outcomes. Additionally, there may have been confounding factors that
- 272 were not accounted for in our analysis, such as socioeconomic status or access to healthcare. These
- 273 factors could potentially influence both vaccination status and disease outcomes.
- 274 Lastly, our study focused on a specific population or setting, which may limit the generalizability
- 275 of the findings to other regions or healthcare settings. Variations in vaccination rates, healthcare
- 276 infrastructure, and population characteristics could affect the observed associations.
- 277 Despite these limitations, our study contributes valuable insights into the association between
- 278 vaccination status, comorbidities, and disease outcomes in COVID-19 patients. Further research

279 with larger sample sizes, more rigorous study designs, and diverse populations is warranted to 280 build upon our findings and provide a more comprehensive understanding of these relationships. 281 **Conclusion**: 282 Our findings suggest that COVID-19 vaccination is associated with a reduced risk of severe 283 disease among individuals with or without comorbidities and decreased risk of mortality among 284 those with comorbidities. However, larger studies are needed to validate these findings and further 285 explore the impact of vaccination on disease outcomes. These findings support the ongoing efforts 286 to promote COVID-19 vaccination as a crucial public health intervention. 287 288 **CONFLICT OF INTEREST** 289 The authors declare that the research was conducted in the absence of any commercial or financial 290 relationship that could be construed as a potential conflict of interest. 291 **FUNDING SOURCES** 292 None 293 **ACKNOWLEDGEMENT** 294 We thank all the patients participating in this study. 295 ETHICAL APPROVAL 296 The study protocol (Code no. 48/2022 P) was approved by Nepal Health Research Council. 297 **CONSENT FOR PUBLICATION** 298 Written informed consent was obtained from the patients for publication of this original article. A 299 copy of the written consent is available for review by the Editor-in-Chief of this journal on request. 300 **AUTHORS CONTRIBUTION** All the authors contributed equally to writing and preparing the manuscript. The final version of 302 the article is approved by all authors. 303 RESEARCH REGISTRATION 304 No new surgical techniques or new equipment/technology was used. 305 PROVENANCE AND PEER REVIEW

Not commissioned, externally peer reviewed.

DATA AVAILABILITY STATEMENT

Datasets generated during and/or analyzed during the current study are available upon reasonable request.

References

307

309

- 311 1. WHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard
- With Vaccination Data. Accessed June 4, 2023. https://covid19.who.int/
- 313 2. Kellam P, Barclay W. The dynamics of humoral immune responses following SARS-
- 314 CoV-2 infection and the potential for reinfection. *J Gen Virol*. 2020;101(8):791-797.
- 315 doi:10.1099/JGV.0.001439
- 316 3. Kissler SM, Tedijanto C, Goldstein E, Grad YH, Lipsitch M. Projecting the transmission
- dynamics of SARS-CoV-2 through the postpandemic period. *Science* (1979).
- 318 2020;368(6493):860-868. doi:10.1126/SCIENCE.ABB5793/SUPPL_FILE/PAPV4.PDF
- Liu W, Fontanet A, Zhang PH, et al. Two-year prospective study of the humoral immune
- response of patients with severe acute respiratory syndrome. *J Infect Dis.*
- 321 2006;193(6):792-795. doi:10.1086/500469
- 322 5. Breakthrough Infections: Coronavirus After Vaccination | Johns Hopkins Medicine.
- Accessed June 4, 2023. https://www.hopkinsmedicine.org/health/conditions-and-
- diseases/coronavirus/breakthrough-infections-coronavirus-after-vaccination
- Monitoring COVID-19 Cases, Hospitalizations, and Deaths by Vaccination Status | CDC.
- Accessed June 4, 2023. https://www.cdc.gov/coronavirus/2019-
- 327 ncov/vaccines/effectiveness/monitoring.html?CDC AA refVal=https%3A%2F%2Fwww.
- 328 cdc.gov%2Fcoronavirus%2F2019-ncov%2Fvaccines%2Feffectiveness%2Fwhy-measure-
- 329 effectiveness%2Fbreakthrough-cases.html
- 330 7. Berlin DA, Gulick RM, Martinez FJ. Severe Covid-19. New England Journal of Medicine.
- 331 2020;383(25):2451-2460.
- doi:10.1056/NEJMCP2009575/SUPPL_FILE/NEJMCP2009575_DISCLOSURES.PDF
- Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus
- Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases
- From the Chinese Center for Disease Control and Prevention. *JAMA*. 2020;323(13):1239-
- 336 1242. doi:10.1001/JAMA.2020.2648
- 337 9. The Oxford/AstraZeneca (ChAdOx1-S [recombinant] vaccine) COVID-19 vaccine: what
- 338 you need to know. Accessed June 6, 2023. https://www.who.int/news-room/feature-
- stories/detail/the-oxford-astrazeneca-covid-19-vaccine-what-vou-need-to-know
- 340 10. Voysey M, Costa Clemens SA, Madhi SA, et al. Single-dose administration and the
- influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1

342 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. *The Lancet*. 343 2021;397(10277):881-891. doi:10.1016/S0140-6736(21)00432-3 344 11. The Janssen Ad26.COV2.S COVID-19 vaccine: What you need to know. Accessed June 345 6, 2023. https://www.who.int/news-room/feature-stories/detail/the-j-j-covid-19-vaccine-346 what-you-need-to-know 347 The Sinopharm COVID-19 vaccine: What you need to know. Accessed June 6, 2023. 12. 348 https://www.who.int/news-room/feature-stories/detail/the-sinopharm-covid-19-vaccine-349 what-vou-need-to-know 350 Tenforde MW, Self WH, Adams K, et al. Association Between mRNA Vaccination and 13. 351 COVID-19 Hospitalization and Disease Severity. JAMA. 2021;326(20):2043-2054. 352 doi:10.1001/JAMA.2021.19499 353 14. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA 354 Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603-2615. 355 doi:10.1056/NEJMOA2034577 356 15. Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-357 CoV-2 Vaccine. N Engl J Med. 2021;384(5):403-416. doi:10.1056/NEJMOA2035389 358 16. Bernal JL, Andrews N, Gower C, et al. Effectiveness of the Pfizer-BioNTech and Oxford-359 AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality 360 in older adults in England: test negative case-control study. BMJ. 2021;373. doi:10.1136/BMJ.N1088 361 362 363 364 365 366 367 368 369 370 371 372 373 374

Graphs and tables




Figure 1: Age category of the study participants





Figure 2: Proportion of participants with by prior infection with COVID-19









Figure 4: Specific type of COVID-19 vaccine received by the vaccinated participants










Figure 7: Proportion of study participants by the number of the doses of vaccine received (specific type of vaccine)






Figure 8: Proportion of study participants who received two vaccine doses by the adherence to recommended dosing interval





493 Tables

Name of the vaccine	Single dose	Received two doses of the vaccine			
Janssen Ad26.COV2.S	10	0			
COVID-19	(100%)				
			RDI*	NRDI	
Sinopharm COVID-19	6	11			
vaccine (Verocell)	(35.29%)	(64.71%)	2	9	
			(11.76%)	(52.94	
			RDI*	NRDI	
AstraZeneca (ChAdOx1-S	7	16			
[recombinant] vaccine)	(30.43%)	(69.57%)	4	12	
			(17.39%)	(52.17	

Table 1: Patients	who receiv	red one or	two doses	of the	vaccines.

	Severity		Outcome	
	Non-severe	Severe	Recovered	Expired
	disease	disease		
Vaccinated	40 (80.00%)	10 (20.00%)	44 (88.00%)	6 (12.00%)
Non-	26 (50.00%)	26 (50.00%)	42 (80.77%)	10 (19.23%)

Table 2: Outcomes among the vaccinated and non-vaccinated patients

	S	everity	Outcome		
	Non-severe disease	Severe disease	Recovered	Expired	
Janssen	4	6	8	2	
Ad26.COV2.S COVID-19	(40.00%)	(60.00%)	(80.00%)	(20.00%)	
Sinopharm	14	3	15	2	
COVID-19 vaccine (Verocell)	(82.35%)	(17.65%)	(88.24%)	(11.76%)	
AstraZeneca	20	3	21	2	
(ChAdOx1-S [recombinant]	(86.96%)	(13.04%)	(91.30%)	(8.70%)	

Table 3: Association between different types of vaccines with severity and mortality of disease

	Severity		Outc	ome
	Non-severe	Severe	Recovered	Expired
	disease	disease		
Recommended	6	0	6	0
dosing interval	(100%)		(100%)	
Not as per	16	5	18	3
recommended	(76.19%)	(23.81%)	(85.71%)	(14.29%)
dosing interval				

Table 4: Severity and outcome among the patients receiving two doses of vaccines who were and were not vaccinated with dosing intervals as per WHO recommendation.

Severity			Outcome	
Last vaccination	Non-severe disease	Severe disease	Recovered	Expired
<=3 months	23 (92.00%)	2 (8.00%)	25 (100.00%)	0
>3 months	17 (68.00%)	8 (32.00%)	19 (76.00%)	6 (24.00%)

Table 5: Severity and outcome among patients receiving last dose of their vaccine within 3 months and greater than 3 months.

		Seve	erity	Outcome	
		Non- severe disease	Severe disease	Recovered	Expired
Comorbidities	Vaccinate	14	2	15	1
absent	d	(87.50%)	(12.50%)	(73.75%)	(6.25%)
	Non-	25	23	41	7
	vaccinated	(52.08%)	(47.92%)	(85.42%)	(14.58%)
Comorbidities	Vaccinate	26	8	29	5
oresent	d	(76.47%)	(23.53%)	(85.29%)	(14.71%)
	Non-	1	3	1	3
	vaccinated	(25.00%)	(75.00%)	(25.00%)	(75.00%)

Table 6: Severity of infection and outcome among vaccinated and non-vaccinated patients

514

Age category	Vaccination status	Non-severe disease	Severe disease	Recovered	Expired
<18 years	Vaccinated	0	0	0	0
	Non-	9	8	14	3
	vaccinated	(52.9%)	(47.1%)	(82.35%)	(17.65%)
18-59 years	Vaccinated	20	5	23	2
		(80.00%)	(20.00%)	(92.00%)	(8.00%)
	Unvaccinated	7	12	14	5
		(36.84%)	(63.16%)	(73.68%)	(26.32%)
>=60 years	Vaccinated	20	5	21	4
-		(80.00%)	(20.00%)	(84.00%)	(16.00%)
	Unvaccinated	10	6	14	2
		(62.50%)	(37.50%)	(87.50%)	(12.50%)

Table 7: Severity and outcome of COVID-19 infections among vaccinated and non-vaccinated groups according to different age category

	S	Severity	Oı	ıtcome
	Non-Severe disease	Severe disease	Recovered	Expired
Prior infection with COVID-19	5 (100%)	0	5 (100%)	0
No Prior infection with COVID-19	61 (62.89%)	36 (37.11%)	81 (83.51%)	16 (16.49%)

Table 8: Prior infection and severity or outcome of current infection